Larimar Therapeutics plans PK run-in study in adolescents, children with FA

Larimar announced it is planning a PK run-in study in adolescents and children with FA. This study which we plan to initiate by year-end, will initially enroll 12-15 adolescent patients who will be randomized 2:1 to receive either nomlabofusp or placebo daily. Study participants can transition to the OLE study after completing the PK run-in study. Larimar announced that all 7 sites of the OLE were activated. The OLE study continues to progress with interim data to be reported in the fourth quarter of the year.